Apr 30 |
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
|
Apr 30 |
Harmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024
|
Apr 30 |
Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline
|
Apr 30 |
Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M
|
Apr 30 |
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
|
Apr 30 |
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
|
Apr 29 |
Harmony Biosciences Q1 2024 Earnings Preview
|
Apr 16 |
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
|
Apr 11 |
Harmony inks licensing deal for sleep disorder therapy
|
Apr 11 |
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
|